Redmile Group’s Immunome IMNM Stock Holding History

Redmile Group’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$104M	Sell	4,911,590 -647,295	-12%	-$13.9M	6.99%	4
2026 Q1	$122M	Sell	5,558,885 -159,500	-3%	-$3.55M	8.05%	4
2025 Q4	$123M	Buy	5,718,385 +695,000	+14%	+$12.2M	9.05%	5
2025 Q3	$58.8M	Buy	5,023,385 +151,160	+3%	+$1.5M	5.72%	6
2025 Q2	$45.3M	Sell	4,872,225 -488,962	-9%	-$4.01M	4.82%	5
2025 Q1	$36.1M	Buy	5,361,187 +533,161	+11%	+$5.12M	3.41%	9
2024 Q4	$51.3M	Sell	4,828,026 -61,528	-1%	-$744K	3.57%	7
2024 Q3	$71.5M	Hold	4,889,554	–	–	4.21%	4
2024 Q2	$59.2M	Hold	4,889,554	–	–	3.58%	5
2024 Q1	$121M	Buy	4,889,554 +1,010,139	+26%	+$20.5M	4.43%	3
2023 Q4	$41.5M	Buy	+3,879,415	New	+$32.3M	1.48%	18

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Redmile Group's IMNM Position: Q2 2026 in Review

Redmile Group reduced its Immunome (IMNM) stake by 12% in Q2 2026, selling an estimated $13.9M and leaving 4,911,590 shares worth $104M. The position accounts for 6.99% of the portfolio, ranked #4.

Redmile Group first reported a position in IMNM in Q4 2023 and has held it in 11 quarters since. The position peaked at $123M in Q4 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

Redmile Group held 4,911,590 shares of Immunome worth $104M as of Q2 2026.
Redmile Group sold 647,295 Immunome shares in Q2 2026, an estimated $13.9M.
Immunome made up 6.99% of Redmile Group's portfolio in Q2 2026, its #4 holding.
Redmile Group first reported a position in Immunome in Q4 2023 and has held it in 11 quarters since.
Redmile Group's Immunome position peaked at $123M in Q4 2025.
202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Redmile Group's 13F filing for Q2 2026, filed 14 Aug 2026.